


Claims:

1. A compound of Formula (II),



or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein

R^1 is $-OR^{1a}$, $-SR^{1a}$, $-NR^{1a}R^{1b}$, $-COR^{1a}$, $-SO_2R^{1a}$, $-C(=O)OR^{1a}$, $-C(=O)NR^{1a}R^{1b}$, $-C(=NR^{1a})NR^{1b}R^{1c}$, $-N(R^{1a})C(=O)R^{1b}$, $-N(R^{1a})C(=O)OR^{1b}$, $-N(R^{1a})C(O)NR^{1b}R^{1c}$, $-N(R^{1a})S(O)NR^{1b}R^{1c}$, $-N(R^{1a})S(O)_2NR^{1b}R^{1c}$, $-NR^{1a}SO_2R^{1b}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is independently and optionally substituted with one or two or three substituents R^{1d} ;

R^{1a} , R^{1b} , and R^{1c} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or two or three substituents selected from halogen, $-C_{1-8}$ alkyl optionally substituted with R^{1e} , cycloalkyl optionally substituted with R^{1e} , heterocyclyl optionally substituted with R^{1e} , aryl optionally substituted with R^{1e} , heteroaryl optionally substituted with R^{1e} , $CH_3-(OCH_2CH_2)_n-$ (wherein n is a number of 3 to 10) or $-OR^{1f}$;

wherein R^{1e} is halogen, nitro, cyano, hydroxy, amino ($-NH_2$), alkylamino, dialkylamino, or $-C_{1-6}$ alkyl optionally substituted with halogen;

wherein R^{1f} is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with $-C_{1-4}$ alkyl or halogen;

R^{1d} , at each occurrence, is independently hydrogen, oxo, $-CN$, $-NO_2$, amino ($-NH_2$), alkylamino, dialkylamino, halogen, haloalkyl, alkyl, haloalkoxy, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl;

Ring A is aryl or heteroaryl;

Het is heterocyclyl;

R^5 is halogen, hydroxy, alkyl, haloalkyl, alkoxy, haloalkoxy, oxo-, or $-C(=O)OR^{5a}$, wherein R^{5a} is hydrogen, alkyl, or haloalkyl;

p is a number of 0, 1, 2 or 3;

R^{6c} is independently hydrogen, halogen, cyano, $-NO_2$, $-OR^{6d}$, $-SR^{6d}$, $-NR^{6d}R^{6e}$, $-COR^{6d}$, $-SO_2R^{6d}$, $-C(=O)OR^{6d}$, $-C(=O)NR^{6d}R^{6e}$, $-C(=NR^{6d})NR^{6e}R^{6f}$, $-N(R^{6d})C(=O)R^{6e}$, $-N(R^{6d})C(=O)OR^{6e}$, $-N(R^{6d})C(O)NR^{6e}R^{6f}$, $-N(R^{6d})S(O)NR^{6e}R^{6f}$, $-N(R^{6d})S(O)_2NR^{6e}R^{6f}$, $-NR^{6d}SO_2R^{6e}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is independently and optionally substituted with one or two or three substituents R^{6g} ;

R^{6d} , R^{6e} and R^{6f} , are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,

cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or two or three substituents R^{6g} ;

R^{6g} , at each occurrence, is independently hydrogen, halogen, cyano, $-\text{NO}_2$, $-\text{OR}^{6h}$, $-\text{SR}^{6h}$, $-\text{NR}^{6h}\text{R}^{6i}$, $-\text{COR}^{6h}$, $-\text{SO}_2\text{R}^{6h}$, $-\text{C}(=\text{O})\text{OR}^{6h}$, $-\text{C}(=\text{O})\text{NR}^{6h}\text{R}^{6i}$, $-\text{C}(=\text{NR}^{6h})\text{NR}^{6i}\text{R}^{6j}$, $-\text{N}(\text{R}^{6h})\text{C}(=\text{O})\text{R}^{6i}$, $-\text{N}(\text{R}^{6h})\text{C}(=\text{O})\text{OR}^{6i}$, $-\text{N}(\text{R}^{6h})\text{C}(\text{O})\text{NR}^{6i}\text{R}^{6j}$, $-\text{N}(\text{R}^{6h})\text{S}(\text{O})\text{NR}^{6i}\text{R}^{6j}$, $-\text{N}(\text{R}^{6h})\text{S}(\text{O})_2\text{NR}^{6i}\text{R}^{6h}$, $-\text{NR}^{6h}\text{SO}_2\text{R}^{6i}$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl,

R^{6h} , R^{6i} and R^{6j} , are independently hydrogen, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl, each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl or heteroaryl is independently and optionally substituted with one or two or three substituents selected from halogen, $-\text{C}_{1-4}\text{alkyl}$, $-\text{C}_{1-4}\text{alkoxy}$, hydroxy, nitro, $-\text{NH}_2$, alkylamino, dialkylamino, or cyano.

2. The compound according to Claim 1, wherein R^1 is $-\text{OR}^{1a}$ or $-\text{NHR}^{1a}$, wherein R^{1a} is $-\text{C}_{1-8}\text{alkyl}$ optionally substituted with one or two or three substituents selected from halogen, $-\text{C}_{1-8}\text{alkyl}$ optionally substituted with R^{1e} , cycloalkyl optionally substituted with R^{1e} , heterocyclyl optionally substituted with R^{1e} , aryl optionally substituted with R^{1e} , heteroaryl optionally substituted with R^{1e} , $\text{CH}_3-(\text{OCH}_2\text{CH}_2)_n-$ (wherein n is a number of 3 to 10), or $-\text{OR}^{1f}$, wherein R^{1e} and R^{1f} are as defined in Claim 1.
3. The compound according to Claim 1, wherein R^1 is $-\text{OR}^{1a}$ or $-\text{NHR}^{1a}$, wherein R^{1a} is a branched $-\text{C}_{4-8}\text{alkyl}$ wherein the branched substituent is at the alpha position with respect to the oxygen or nitrogen atom.
4. The compound according to Claim 1, wherein R^1 is $-\text{OR}^{1a}$ or $-\text{NHR}^{1a}$, wherein R^{1a} is butan-2-yl, pentan-2-yl, pentan-3-yl, heptan-2-yl, heptan-3-yl, heptan-4-yl, octan-2-yl, octan-3-yl, octan-4-yl, or octan-5-yl.
5. The compound according to any one of Claims 1-4, wherein R^5 is halogen, hydroxy, $-\text{C}_{1-8}\text{alkyl}$, $-\text{haloC}_{1-8}\text{alkyl}$, $-\text{C}_{1-8}\text{alkoxy}$, $-\text{haloC}_{1-8}\text{alkoxy}$, or $-\text{C}(=\text{O})\text{OR}^{5a}$, wherein R^{5a} is hydrogen, $-\text{C}_{1-8}\text{alkyl}$, or $-\text{haloC}_{1-8}\text{alkyl}$; and p is a number of 0, 1, or 2.
6. The compound according to any one of Claims 1-5, wherein R^5 and Het-R^6 are at ortho positions on ring A.
7. The compound according to any one of Claims 1-6, wherein Ring A is phenyl or 5- to 8-membered heteroaryl comprising one or two or three heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur as ring members.
8. The compound according to any one of Claims 1-7, wherein Het is a monocyclic heterocyclyl, or a fused bicyclic heterocyclyl; or a spiro bicyclic heterocyclyl.
9. The compound according to any one of Claims 1-8, wherein Het is a 4-, 5-, 6-, 7- or 8-membered saturated monocyclic heterocyclyl ring comprising one, two or three heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur as ring members, wherein Het is optionally substituted with one or two or three substituents R^{6c} .
10. The compound according to claim 9, wherein Het is a 5- or 6-membered saturated

monocyclic heterocyclyl ring comprising one or two nitrogen heteroatoms as ring members.

11. The compound according to claim 9, wherein Het is pyrrolidinyl (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), piperidinyl (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl), triazolyl (e.g., 1H-1,2,4-triazol-1-yl), azepanyl (e.g., azepan-2-yl, azepan-3-yl, azepan-4-yl, azepan-5-yl), diazepanyl (e.g., 1,4-diazepan-1-yl, 1,4-diazepan-2-yl, 1,4-diazepan-3-yl, 1,4-diazepan-4-yl), piperazinyl (e.g., piperazin-1-yl, piperazin-2-yl, piperazin-3-yl) or morpholino.

12. The compound according to claim 9, wherein R^{6c} is $-COR^{6d}$, wherein R^{6d} is $-C_{1-8}$ alkyl (preferably C_{1-6} alkyl, more preferably C_{1-4} alkyl) optionally substituted with one or two substituents R^{6g} , wherein R^{6g} is $-NR^{6h}R^{6i}$, $-N(R^{6h})C(=O)R^{6i}$, $-C_{1-8}$ alkyl, aryl or heteroaryl, wherein R^{6h} and R^{6i} are each independently hydrogen or $-C_{1-8}$ alkyl (preferably C_{1-6} alkyl, more preferably C_{1-4} alkyl).

13. The compound according to claim 9, wherein R^{6c} is

$-COR^{6d}$, wherein R^{6d} is $-C_{2-8}$ alkenyl or heterocyclyl;

$-C_{1-8}$ alkoxy;

$-C_{1-8}$ alkyl, optionally substituted with one or two substituents R^{6g} , wherein R^{6g} is $-OR^{6h}$, $-NR^{6h}R^{6i}$, heterocyclyl, aryl, wherein R^{6h} and R^{6i} are as defined in Claim 1;

heterocyclyl, optionally substituted with one substituent R^{6g} which is heterocyclyl; $-C(=O)NR^{6d}R^{6e}$, wherein R^{6d} and R^{6e} are independently hydrogen, $-C_{1-8}$ alkyl (preferably $-C_{1-3}$ alkyl), or aryl, said $-C_{1-8}$ alkyl or aryl is independently and optionally substituted with halogen or $-C_{1-4}$ alkyl; or,

$-NR^{6d}R^{6e}$, wherein R^{6d} and R^{6e} are independently hydrogen, or $-C_{1-8}$ alkyl.

14. The compound according to Claim 9, wherein R^{6c} is

acetyl, 2-(dimethylamino)acetyl, 2-(dimethylamino)acetyl, aminoacetyl, 2-(methylamino)acetyl, 3-(dimethylamino)propanoyl, 4-(dimethylamino)butanoyl, 5-(dimethylamino)pentanoyl, (2S,3S)-2-amino-3-methylpentanoyl, 2-(methylamino)acetyl, 2-amino-4-methylpentanoyl, 2-amino-3-methylbutanoyl, 2-(dimethylamino)acetyl, phenylpropanoyl, 2-(piperazin-1-yl)acetyl, acryloyl, piperazine-2-carbonyl, piperidine-4-carbonyl, pyrrolidine-2-carbonyl, or 2-(N-methylacetamido)acetyl;

methyl, ethyl, isobutyl, methoxymethyl, 2-methoxyethyl, (methylamino)methyl, 2-(dimethylamino)ethyl, (dimethylamino)methyl, 2-aminoethyl, 2-(methylamino)ethyl, 2-(dimethylamino)ethyl, morpholinomethyl, or phenethyl;

4-morpholinopiperidin-1-yl;

dimethylcarbamoyl, isopropylcarbamoyl, or 2,4,5-trifluorophenylcarbamoyl; or dimethylamino, or amino.

15. The compound according to claim 9, wherein Het is

pyrrolidinyl, optionally substituted with one or two or three substituents selected from methyl, (dimethylamino)methyl, or dimethylamino; or

piperazinyl, optionally substituted with one or two or three substituents selected from acryloyl, 2-(dimethylamino)acetyl, aminoacetyl, 2-(methylamino)acetyl, 3-

(dimethylamino)propanoyl, 2-(piperazin-1-yl)acetyl, piperazine-2-carbonyl, 4-(dimethylamino)butanoyl, 5-(dimethylamino)pentanoyl, methyl, piperidine-4-carbonyl, acetyl, 2-(N-methylacetamido)acetyl, isopropylcarbamoyl, 2,4,5-trifluorophenylcarbamoyl, (2S,3S)-2-amino-3-methylpentanoyl, 2-methoxyethyl, 2-(methylamino)acetyl, ethyl, isobutyl, pyrrolidine-2-carbonyl, 2-amino-4-methylpentanoyl, 2-amino-3-methylbutanoyl, 2-(dimethylamino)acetyl, 2-(methylamino)ethyl, 2-(dimethylamino)ethyl, amino, phenylpropanoyl, propylsulfonyl, or 2-aminoethyl; or

piperidinyl, optionally substituted with one or two or three substituents selected from 2-(dimethylamino)acetyl, methoxy, methoxymethyl, (methylamino)methyl, 4-morpholinopiperidin-1-yl, morpholinomethyl, 2-(dimethylamino)ethyl, phenethyl, (dimethylamino)methyl, amino, dimethylamino, or dimethylcarbamoyl; or

azepan-1-yl or 1,4-diazepan-1-yl; or

octahydro-2H-isoindol-2-yl; or

morpholino; or

8-azaspiro[4.5]decan-8-yl, 2,7-diazaspiro[3.5]nonan-7-yl, 2,8-diazaspiro[4.5]decan-2-yl, 2,7-diazaspiro[3.5]nonan-2-yl, 2,8-diazaspiro[4.5]decan-8-yl, (1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl.

16. The compound according to claim 9, wherein Het is

1-methylpyrrolidin-3-yl, pyrrolidin-1-yl, 3-((dimethylamino)methyl)pyrrolidin-1-yl, or 3-(dimethylamino)pyrrolidin-1-yl; or

piperazin-1-yl, 4-acryloylpiperazin-1-yl, 4-(2-(dimethylamino)acetyl)piperazin-1-yl, (4-aminoacetyl)piperazin-1-yl, piperazin-1-yl, 4-(2-(methylamino)acetyl)piperazin-1-yl, 4-(3-(dimethylamino)propanoyl)piperazin-1-yl, 4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl, 4-(piperazine-2-carbonyl)piperazin-1-yl, 4-acryloylpiperazin-1-yl, 4-(4-(dimethylamino)butanoyl)piperazin-1-yl, 4-(5-(dimethylamino)pentanoyl)piperazin-1-yl, 3,5-dimethylpiperazin-1-yl, 4-(piperidine-4-carbonyl)piperazin-1-yl, 4-acetylpiperazin-1-yl, 4-(2-(N-methylacetamido)acetyl)piperazin-1-yl, 4-(isopropylcarbamoyl)piperazin-1-yl, 4-(2,4,5-trifluorophenylcarbamoyl)piperazin-1-yl, 4-(3,5-dimethylpiperazin-1-yl, 4-((2S,3S)-2-amino-3-methylpentanoyl)piperazin-1-yl, 4-(2-methoxyethyl)piperazin-1-yl, 4-(2-(methylamino)acetyl)piperazin-1-yl, 4-ethylpiperazin-1-yl, 4-isobutylpiperazin-1-yl, 4-(pyrrolidine-2-carbonyl)piperazin-1-yl, 4-(2-amino-4-methylpentanoyl)piperazin-1-yl, 4-(2-amino-3-methylbutanoyl)piperazin-1-yl, 4-(2-(dimethylamino)acetyl)piperazin-1-yl, (S)-2-methylpiperazin-1-yl, (R)-2-methylpiperazin-1-yl, 4-(2-(methylamino)ethyl)piperazin-1-yl, 4-(2-(dimethylamino)ethyl)piperazin-1-yl, 4-(2-amino-3-phenylpropanoyl)piperazin-1-yl, 4-(propylsulfonyl)piperazin-1-yl, 4-(2-aminoethyl)piperazin-1-yl, or 3-methylpiperazin-1-yl; or

piperidin-4-yl, 4-(2-(dimethylamino)acetyl)piperidin-1-yl, piperidin-3-yl, piperidin-4-yl, piperidin-1-yl, piperidin-4-yl, 4-methoxypiperidin-1-yl, 4-(methoxymethyl)piperidin-1-yl, 4-((methylamino)methyl)piperidin-1-yl, (4-morpholinopiperidin-1-yl)pyridin-3-yl, 4-(morpholinomethyl)piperidin-1-yl, 4-(2-(dimethylamino)ethyl)piperidin-1-yl, 1-phenethylpiperidin-4-yl, 4-((dimethylamino)methyl)piperidin-1-yl, 4-aminopiperidin-1-yl, 4-

(dimethylamino)piperidin-1-yl, or 4-(dimethylcarbamoyl)piperidin-1-yl.

17. The compound according to any one of Claims 1-6, wherein ring A is phenyl, and the methylene group and Het on the phenyl ring are in para positions of the phenyl ring, and said phenyl ring is further optionally substituted with one R⁵, wherein R⁵ is defined as in each embodiment above.

18. The compound according to any one of Claims 1-6, wherein ring A is pyridyl, and the methylene group and Het on the pyridyl ring are in para positions of the pyridyl ring, and said pyridyl ring is further optionally substituted with one R⁵, wherein R⁵ is defined as in each embodiment above.

19. A compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, selected from any one of Examples B1 to B247.

20. A pharmaceutical composition comprising the compound according to any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

21. A use of a compound according to any one of Claims 1-19, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for modulating TLR7

22. A use of a compound according to any one of Claims 1-19, or a pharmaceutically acceptable salt thereof as a TLR7 agonist in the manufacture of a medicament for treating a disease or disorder.

23. The use according to claim 22, wherein the disease or disorder is cancer.